Daily Bulletin

Men's Weekly

.

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1] which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate

SYDNEY, Dec. 14, 2022 /PRNewswire/ -- Actinogen...

Read more: Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical...

Business News

Finding Reliable Equipment Hire for Your Construction Projects

Construction projects are a heavy reliance on getting the right equipment to the right place, at the right time. Whether you're breaking ground, moving earth, paving roads, or just building, heavy m...

Daily Bulletin - avatar Daily Bulletin

Townsville Woman’s Solution for Evacuations – Hit the Road

Angela lives in Townsville’s Railway Estate with her two beloved labradors. Railway Estate is just one Townsville area hit so regularly by flooding that residents have all but given up. After the 2019...

Daily Bulletin - avatar Daily Bulletin

Tuning Strategies for Modern Trucks: Putting SCT X4 Performance to the Test

The Case for Aftermarket Tuning in Modern Trucks Factory programmers aren't trying to thrill you. They’re chasing emissions compliance, warranty safety nets, and broad market compatibility. That co...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business